Filing identity and period
Important discrepancy: The request metadata identifies Lisata Therapeutics, Inc. and 2017 Q1, but the supplied filing is Caladrius Biosciences, Inc.’s Form 10-Q for the quarter ended March 31, 2018, signed May 10, 2018. The summary below reflects the supplied filing.
Business context
Caladrius develops cell therapies for cardiovascular and autoimmune diseases. Its programs included CLBS12 for critical limb ischemia, CLBS14-CMD for coronary microvascular dysfunction, CLBS14-RfA for refractory angina, and CLBS03 for recent-onset type 1 diabetes. The PCT manufacturing business was sold to Hitachi in May 2017 and is reported as discontinued operations.
Financial performance and liquidity
- Revenue: The filing reports no revenue from continuing operations for Q1 2018; therefore, a continuing-operations margin is not applicable. Q1 2017 discontinued operations included $10.3 million of revenue.
- Operating expenses and loss: Operating expenses were $5.16 million, down 20% from $6.43 million. Research and development was $2.26 million, down 39%; general and administrative expense was $2.90 million, up 7%. Operating loss was $5.16 million.
- Net loss: $4.98 million, or $0.52 per basic and diluted share, versus a $9.79 million total net loss, or $1.12 per share, in Q1 2017. The prior-year total included $3.16 million of discontinued-operations losses; continuing-operations loss improved from $6.64 million to $4.98 million.
- Cash flow: Net cash used in continuing operations was $6.30 million, versus $4.59 million in Q1 2017. Investing used $1.19 million, primarily net purchases of marketable securities; financing used $0.07 million. Cash, cash equivalents and restricted cash declined by $7.56 million during the quarter.
- Liquidity: At March 31, cash and cash equivalents were $21.60 million, restricted cash $5.01 million, and marketable securities $26.98 million—about $53.59 million combined. Working capital was approximately $46.6 million.
- Debt and equity: Current notes payable were $92,000; total liabilities were $11.40 million and stockholders’ equity was $45.59 million. The filing describes equipment-financing notes maturing within one year.
Material changes and management commentary
- R&D spending fell as CLBS03 enrollment and manufacturing costs ended and the study moved into follow-up. Ischemic-repair spending rose to $2.1 million from $0.1 million, primarily for the CLBS12 and CLBS14-CMD programs.
- Management reported that the CLBS03 Phase 2 study had enrolled 110 participants; an interim analysis was described as well tolerated and non-futile. These are company-reported trial updates, not evidence of efficacy or approval.
- CLBS12’s Japanese Phase 2 study opened for enrollment in December 2017, with first-patient treatment announced in March 2018. It received Japan’s SAKIGAKE designation. The company was seeking a Japanese partner.
- Management stated existing cash was expected to fund CLBS03 development and other operating expenses for at least 12 months after issuance of the financial statements. It also noted that future financing may be needed and may be unavailable on acceptable terms.
Outlook, risks and unusual items
- The company had an at-the-market common-stock sales agreement allowing up to $12 million in offerings; no shares had been sold under it as of March 31, 2018. Any sales could dilute shareholders.
- CIRM set the T-Rex Study award at $8.6 million, of which $7.9 million had been received by quarter-end. Funding recognition is tied to the award period and reduces related R&D expense.
- A $5.0 million escrow from the PCT sale was classified as restricted cash. The filing expected release in June 2018, subject to indemnification claims and disputed claims. A separate potential $5.0 million PCT revenue milestone was valued at zero at the sale date and depended on specified cumulative revenue through 2018.
- Risks highlighted include the need for capital, clinical and regulatory uncertainty, trial enrollment and execution, commercialization and partnership prospects, and intellectual-property and regulatory challenges. The company reported no material changes to previously disclosed risk factors and no material pending legal claims expected to affect its financial condition or operating results.
- Management stated disclosure controls were effective at the reasonable-assurance level and reported no material changes in internal control over financial reporting during the quarter.
Key facts investors should verify
- Confirm the issuer and period: the supplied filing is Caladrius Biosciences’ Q1 2018 report, not a Lisata Therapeutics 2017 Q1 report.
- Check subsequent clinical results, regulatory developments, and partner or funding progress for the disclosed cell-therapy programs.
- Track operating cash use against management’s stated minimum 12-month runway and assess whether additional financing is required.
- Verify the amount and timing of the PCT escrow release, any indemnification deductions, and whether the contingent milestone becomes payable.
- Monitor use of the $12 million ATM facility and resulting share dilution.